Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report)'s stock price fell 8.6% during mid-day trading on Tuesday . The company traded as low as $11.84 and last traded at $11.89. 71,625 shares were traded during mid-day trading, a decline of 80% from the average session volume of 357,416 shares. The stock had previously closed at $13.00.
Analyst Ratings Changes
A number of brokerages have issued reports on BCAX. RODMAN&RENSHAW raised Bicara Therapeutics to a "strong-buy" rating in a report on Tuesday, November 5th. Wedbush reaffirmed an "outperform" rating and set a $31.00 target price on shares of Bicara Therapeutics in a research note on Wednesday. Rodman & Renshaw began coverage on Bicara Therapeutics in a research note on Tuesday, November 5th. They set a "buy" rating and a $48.00 target price for the company. Finally, HC Wainwright upped their target price on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a "buy" rating in a research note on Monday, January 27th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $41.20.
Read Our Latest Analysis on BCAX
Bicara Therapeutics Stock Up 2.7 %
The company has a 50-day moving average of $14.98.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). As a group, analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.
Institutional Trading of Bicara Therapeutics
Large investors have recently made changes to their positions in the company. First Turn Management LLC purchased a new stake in shares of Bicara Therapeutics during the third quarter worth approximately $14,324,000. Geode Capital Management LLC purchased a new stake in Bicara Therapeutics in the 3rd quarter valued at $1,239,000. Vestal Point Capital LP purchased a new stake in Bicara Therapeutics in the 3rd quarter valued at $10,825,000. FMR LLC purchased a new stake in Bicara Therapeutics in the 3rd quarter valued at $57,913,000. Finally, Braidwell LP purchased a new stake in Bicara Therapeutics in the 3rd quarter valued at $42,219,000.
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
See Also
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
